Funding Opportunity PAR-21-298 from the NIH Guide for Grants and Contracts. The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods) in adolescent and young women. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies. It also encourages biobehavioral and behavioral/social studies to identify MPT end user preferences factors (look, feel, effectiveness, safety and duration of action) and other behavioral/social factors that could promote increased MPT use in adolescent and young women.

Funding Opportunity RFA-DK-21-024 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for the Pediatric Centers of Excellence in Nephrology (PCEN) to support basic, translational and clinical research in pediatric kidney disease. The goals of this program are: 1. to attract new scientific expertise to the study of human pediatric renal physiology, kidney development, and pediatric kidney disorders; 2. to encourage multidisciplinary research in these areas; and 3. to develop the pediatric nephrology research community through a national Pilot and Feasibility grant program leading to innovative approaches to study kidney disease in children and the eventual submission of substantial, competitive, investigatorinitiated research applications. The PCEN will complement the OBrien Kidney and Urological Research Centers and are expected to leverage existing institutional resources which may include Clinical Translational Science Awards, Institutional Network Awards for Promoting Kidney, Urologic, and Hematologic Research Training (U2C/TL1), and other NIDDK-Division of Kidney, Urologic and Hematologic Diseases (KUH)-funded consortia.

Funding Opportunity PAR-21-295 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity of thought in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA.

Funding Opportunity PAR-21-296 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity of thought in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA

Funding Opportunity RFA-CA-21-054 from the NIH Guide for Grants and Contracts. The TBEL program aims to integrate basic and translational cancer research concepts to examine the direct causal relationships and interactions of an early lesion, its microenvironment and host-systemic factors as co-organizers of tumor initiation (or suppression) and malignant progression. The ultimate goals of the TBEL program are to further understand the biological and pathophysiological mechanisms driving or restraining precancers and early cancers and facilitate biology-backed precision prevention approaches. The FOA will utilize the U54 (Specialized Center--Cooperative Agreements) activity code. Each TBEL Center shall have a unique thematic focus and be structured to test hypotheses that bridge basic and translational research in a synergistic and iterative fashion. Collectively, TBEL Centers will operate as a network that will inform future, rationally-design modes of intervention that are founded on strong biological mechanisms and be comprehensive, multi-dimensional, and appropriately tailored to the degree of malignant potential of an early lesion.

Funding Opportunity RFA-CA-21-055 from the NIH Guide for Grants and Contracts. The TBEL program aims to integrate basic and translational cancer research concepts to examine the direct causal relationships and interactions of an early lesion, its microenvironment, and host-systemic factors as co-organizers of tumor initiation (or suppression) and malignant progression. The ultimate goals of the TBEL program are to further understand the biological and pathophysiological mechanisms driving or restraining precancers and early cancers and facilitate biology-backed precision prevention approaches. The responsibilities of the CDMC will be to (1) coordinate consortium-wide meetings and conferences, and cross-consortium collaborative activities; (2) provide statistical and computational analysis support; and (3) establish program data hub for data capture, curation and management, and protocol development and registration. The other scientific unit of the TBEL program will comprise the U54 Centers, which will be structured to efficiently bridge gaps between basic and translational research on early lesions and their microenvironments. This Notice is being provided to allow potential applicants sufficient time to develop a responsive TBEL Coordinating and Data Management Center application. The FOA is expected to be published in May 2021 with an anticipated application due date in October 2021. Details of the planned pre-application webinar will be announced in the Guide after publication of the FOA. The companion notice for the TBEL U54 Centers is: NOT-CA-21-XXX. The FOA will not be restricted to specific early lesion/cancer type(s).

Notice NOT-HL-21-029 from the NIH Guide for Grants and Contracts

Notice NOT-OH-21-011 from the NIH Guide for Grants and Contracts

Our Experimental Error columnist remembers a key figure from grad school

Notice NOT-AG-21-060 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-340 from the NIH Guide for Grants and Contracts

Notice NOT-EB-21-020 from the NIH Guide for Grants and Contracts

Notice NOT-HL-21-020 from the NIH Guide for Grants and Contracts

Notice NOT-HL-21-015 from the NIH Guide for Grants and Contracts

Notice NOT-HL-21-027 from the NIH Guide for Grants and Contracts

Notice NOT-OH-21-012 from the NIH Guide for Grants and Contracts

$200000 -$210000: Telethon Kids Institute: The Opportunity  Here at Telethon Kids Institute we bring together the best minds and pursue the most promising science. We have a passion to see o... Nedlands (Suburb), Perth (AU)

Notice NOT-NR-21-007 from the NIH Guide for Grants and Contracts

Notice NOT-AG-21-059 from the NIH Guide for Grants and Contracts

£70-75 per hour Ltd: CK Group: CK Group are recruiting for a Senior Statistician to join a company in the Pharmaceutical industry, working remotely on a contract basis initially for 12... Cambridge